evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews · HIV/AIDS

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in progression of Kaposi's sarcoma compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ complete response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ partial response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ stable disease compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review